Investors in Life Science

Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra). Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA. Based in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count nearly 95 professionals, of which 58 investment professionals. It is structured as a partnership and managed by a board of 10 partners. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming. Andera Partners has been certified carbon neutral since 2018.

McWin is a private investment firm that focuses on Food Tech, Life Science, Clean Tech, Mobility Space Tech, Digitalization, and Fintech.McWin is a private equity firm founded by Henry McGovern and Steven K. Winegar partnering with exceptional founders and CEOs daring sustainable disruption, principally in the foodservice and food technology sectors.

Mérieux Equity Partners is one of the most recognized and active European Investment firms in the Healthcare sector. We support the development and growth of high-potential companies from business launch to large scale deployment through capital investment and tailor-made support based on our strong sector expertise and international network. We are an agile investor with a flexible approach in terms of minority or majority stakes. Our main focus is partnering with and investing alongside management teams.

At Crédit Mutuel Innovation, our focus is on investing in innovative companies in deeptech, digital, and life sciences sectors, leveraging our €4 billion in capital under management. We provide equity tickets ranging from €1 to €20 million to support entrepreneurs in realizing their growth potential. Beyond financial investment, we foster long-term relationships by connecting companies within our ecosystems, recognizing that creating a world leader often requires sustained support over more than 5 years. This approach ensures sustainable development and mutual success for our portfolio companies and partners.

Kurma Partners is a leading European venture capital group specializing in healthcare, managing €470 million in assets. Our firm operates through two dedicated franchises: Kurma Biofund, which focuses on therapeutics (currently active with fund KBIII), and Kurma Diagnostics, which focuses on diagnostic and digital health (currently active with fund Kurma Dx2). We are committed to supporting innovation in healthcare by investing in promising companies that are poised to make significant advancements in therapeutic treatments and diagnostic technologies.

redalpine is the Swiss venture capital firm that empowers GameChangers. Founded in 2006, redalpine brings together financial investment, operational expertise, and a vast international network to help ambitious entrepreneurs transform their vision into a reality. With over €1bn in assets under management and a disciplined, sector-agnostic investment strategy, the firm has backed some of Europe's most disruptive companies, including N26, Taxfix, Inkitt, 9fin, Carvolution, Zenjob, vivenu, and Umiami. redalpine has over 95 companies in its portfolio and invests Europe-wide from its offices in Zurich and Berlin.

Integra Holdings is a unique venture fund that combines academic excellence, funding and R&D guidance together with a strong and proven business network — the most important elements necessary to bring academic innovation to the market. Focusing on an exclusive selection of biotech companies with proprietary solutions and a competitive advantage in their respective fields, Integra takes a hands-on approach by providing our portfolio companies the strategic planning and business development necessary to bring their technology to the market. Founded by Yissum, the Hebrew University's technology transfer company, Integra capitalizes on the innovative applied research constantly flowing from the renowned Hebrew University of Jerusalem, Israel.

We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.

Healthcare & Technology Venture Capital since 2001. Vi Partners is the longest-established Swiss Venture Capital firm. For more than 20 years, Vi Partners has been supporting innovative Technology and Healthcare companies, investing over CHF 330m in 66 startups. Vi Partners-managed funds are backed by Switzerland's most visible companies and institutions, including ETH Zurich, ABB, Buhler, Credit Suisse, Hilti, McKinsey, Nestlé, Schindler, Sulzer, Suva and ZKB as well as the European Investment Fund and many other institutional investors.

Since 1998, we at Auriga Partners have supported entrepreneurs from the creation of their company through all stages of development, up to their exit via merger and acquisition or IPO. As pioneers in venture capital in France, we have reinvented ourselves into a multi-specialist investor, dedicated to bringing together specific expertise on future themes or territories—both in unlisted and listed companies.

i&i Prague is a bio-innovation center partner for biotech innovations and smart money investments.i&i Prague is located in the heart of Europe, specializing in identifying and investing in new inventions in Drug Discovery, Diagnostics, MedTech, and other Life Science fields. They support projects from academic institutions.

We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options. Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux. We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technology. The amount we aim to invest over the life time of our portfolio companies is up to CHF 10 million.